"Protein Kinase C beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
PKC beta encodes two proteins (PKCB1 and PKCBII) generated by alternative splicing of C-terminal exons. It is widely distributed with wide-ranging roles in processes such as B-cell receptor regulation, oxidative stress-induced apoptosis, androgen receptor-dependent transcriptional regulation, insulin signaling, and endothelial cell proliferation.
| Descriptor ID |
D064546
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.725.049
|
| Concept/Terms |
Protein Kinase C beta2- Protein Kinase C beta2
- PKCbeta2
- Protein Kinase C-beta(II)
- PKCBII
- PKC-beta II
- PKC beta II
- Protein Kinase C beta I
- Protein Kinase C-beta (II)
- PKC beta 2
- beta 2, PKC
- Protein Kinase C beta II
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase C beta".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase C beta".
This graph shows the total number of publications written about "Protein Kinase C beta" by people in this website by year, and whether "Protein Kinase C beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase C beta" by people in Profiles.
-
Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Hum Mol Genet. 2019 06 15; 28(12):2014-2029.
-
Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1). Expert Opin Ther Pat. 2016; 26(4):523-8.
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
-
Identification of p38? as a therapeutic target for the treatment of S?zary syndrome. J Invest Dermatol. 2015 Feb; 135(2):599-608.
-
A RANKL-PKC?-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev. 2013 Apr 15; 27(8):955-69.
-
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther. 2009 Jul; 8(7):1772-8.
-
Chronic PKC-beta activation in HT-29 Cl.19a colonocytes prevents cAMP-mediated ion secretion by inhibiting apical membrane current generation. Am J Physiol Gastrointest Liver Physiol. 2006 Aug; 291(2):G318-30.
-
Chronic PKC-beta2 activation in HT-29 Cl.19a colonocytes prevents cAMP-mediated ion secretion by inhibiting apical membrane CFTR targeting. Am J Physiol Gastrointest Liver Physiol. 2006 Aug; 291(2):G331-44.
-
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes. 2005 Jan; 54(1):85-91.
-
Overexpression of PKC-betaI and -delta contributes to higher PKC activity in the proximal tubules of old Fischer 344 rats. Am J Physiol Renal Physiol. 2003 Dec; 285(6):F1100-7.